NYSE · Healthcare
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
As-reported financials and recent SEC filings for CHARLES RIVER LABORATORIES INTERNATIONAL, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.02B
Net income
$-144.3M
Net margin
-3.6%
Diluted EPS
$-2.91
ROE
-4.6%
P/E (TTM)
—
Market cap
$10.39B
Debt / equity
0.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Gross profit | — | — | — | — | — |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M |
| Net income | $-144.3M | $22.2M | $474.6M | $486.2M | $391.0M |
| Diluted EPS | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →42026-06-03
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →Go deeper on CRL
Search CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.